GCC Nurse Dyslipidaemia Guide

Lipid Panel Interpretation

Parameter	Definition	GCC Reference Range	Clinical Significance
Total Cholesterol (TC)	Sum of all cholesterol fractions (LDL + HDL + VLDL)	Desirable <5.2 mmol/L (<200 mg/dL)	Screening marker; alone insufficient for risk stratification
LDL-C	Low-density lipoprotein cholesterol — primary atherosclerotic driver	Optimal <2.6 mmol/L; high-risk targets vary (see Tab 2)	Primary treatment target; calculated via Friedewald or direct measurement
HDL-C	High-density lipoprotein — reverse cholesterol transport	Men >1.0 mmol/L; Women >1.2 mmol/L	Low HDL = independent CVD risk factor; raising HDL alone not proven beneficial
Triglycerides (TG)	Stored fat form; reflect dietary fat and carbohydrate intake	Normal <1.7 mmol/L; Borderline 1.7–5.6; High >5.6 mmol/L; Very High >11 mmol/L	Pancreatitis risk when >11 mmol/L; residual CVD risk marker
Non-HDL Cholesterol	TC minus HDL-C; includes all atherogenic particles	Desirable <3.4 mmol/L for moderate risk	Better CVD predictor than LDL-C alone, especially in TG elevation; target = LDL target + 0.8 mmol/L
ApoB	Apolipoprotein B — one per atherogenic particle (VLDL/IDL/LDL/Lp(a))	Optimal <0.65 g/L (very high risk); <0.8 g/L (high risk)	Most accurate particle count; useful when LDL-C and TG discordant
Lp(a)	Lipoprotein(a) — genetically determined; independent risk factor	Normal <75 nmol/L (<30 mg/dL); elevated >125 nmol/L	Not lowered by statins; measure once in lifetime; elevated in FH

Friedewald Equation (LDL-C Calculation)

LDL-C = TC − HDL-C − (TG / 2.2) [mmol/L] | LDL-C = TC − HDL-C − (TG / 5) [mg/dL]
Note: Invalid when TG >4.5 mmol/L — use direct LDL measurement in these patients.

Fasting vs Non-Fasting Samples

Non-Fasting (Preferred for Routine Screening)

TC, HDL-C, non-HDL-C, ApoB — minimally affected by food
Triglycerides increase ~0.3 mmol/L post-meal (peak 3–4 hrs)
ESC 2021: non-fasting samples acceptable for initial screening
More practical — reduces patient burden and missed appointments
If non-fasting TG >5 mmol/L → repeat fasting sample

GCC practice: many labs still require fasting — educate patients: 9–12 hr fast, water allowed, medications as usual (except fibrates if TG monitoring).

When Fasting is Required

Monitoring fibrate therapy (TG accuracy)
Suspected severe hypertriglyceridaemia (>5 mmol/L non-fasting)
Calculating Friedewald LDL-C accurately
Post-pancreatitis lipid monitoring
Familial hypertriglyceridaemia phenotyping
When clinical decision hinges on exact TG value

Ramadan consideration: fasting lipid panels taken during Ramadan may not reflect true baseline — schedule testing 4–6 weeks after Eid.

Lipoprotein Types

Lipoprotein	Origin	Main Lipid	Atherogenicity	Clinical Relevance
Chylomicrons	Intestine (dietary fat)	Triglycerides (85–88%)	Minimal	Very large; cleared rapidly; elevation causes creamy plasma
VLDL	Liver (endogenous TG)	Triglycerides (55–65%)	Moderate	TG-rich; elevated in metabolic syndrome; precursor to IDL/LDL
IDL	VLDL catabolism	TG + Cholesterol	Moderate-High	Remnant particle; elevated in Type III dyslipidaemia (apoE2/E2)
LDL	IDL catabolism	Cholesterol (45–50%)	High	Primary atherosclerotic particle; primary treatment target
HDL	Liver/Intestine	Phospholipids + Cholesterol	Protective	Reverse cholesterol transport; anti-inflammatory; low level = risk
Lp(a)	Liver (LDL + apolipoprotein(a))	Cholesterol + apolipoprotein(a)	High	Genetically determined; prothrombotic; not lowered by statins

Secondary Causes of Dyslipidaemia

Always exclude secondary causes before initiating lipid-lowering therapy. Very common in GCC populations.

Endocrine / Metabolic

Hypothyroidism: Elevated LDL-C, elevated TG — always check TSH before starting statin
Type 2 Diabetes: Low HDL, elevated TG, small dense LDL (atherogenic pattern) — very prevalent in GCC
Obesity: Elevated TG, low HDL, elevated VLDL — central adiposity drives hepatic VLDL overproduction
Cushing's syndrome: Elevated TG and LDL
Polycystic Ovarian Syndrome: Low HDL, elevated TG, insulin resistance

Renal / Hepatic

Nephrotic Syndrome: Markedly elevated LDL-C, elevated TG — urinary apolipoprotein loss drives hepatic overproduction
Chronic Kidney Disease: Elevated TG, low HDL, altered LDL metabolism
Cholestasis: Elevated TC — formation of Lp-X; hepatic dysfunction impairs bile acid synthesis

Lifestyle / Dietary

Alcohol excess: Elevated TG (stimulates hepatic VLDL synthesis), elevated HDL transiently
High refined carbohydrate diet: Elevated TG — extremely relevant in GCC
Sedentary lifestyle: Low HDL, elevated TG

Medications (Common in GCC)

Drug Class	Effect on Lipids
Thiazide diuretics	↑ TC, ↑ LDL, ↑ TG
Beta-blockers (non-selective)	↑ TG, ↓ HDL
Corticosteroids	↑ TC, ↑ TG, ↑ LDL
Atypical antipsychotics	↑ TG, ↑ LDL, weight gain
Antiretrovirals (PIs)	↑ TG, ↑ LDL, lipodystrophy
Isotretinoin	↑↑ TG — monitor closely
Immunosuppressants (ciclosporin)	↑ LDL-C
Oestrogens (oral)	↑ TG

Nursing Action: Before attributing dyslipidaemia to primary cause, check: TSH, fasting glucose/HbA1c, urine albumin:creatinine ratio, LFTs, medication review.

Cardiovascular Risk Calculators

SCORE2 (ESC 2021 — Recommended)

Estimates 10-year risk of fatal/non-fatal CVD events
Variables: age, sex, smoking, systolic BP, non-HDL cholesterol
Region-specific: SCORE2 uses European data (low/moderate/high/very high risk regions)
GCC countries: use High Risk region coefficients (similar to Eastern Europe)
SCORE2-OP for patients ≥70 years

Framingham Risk Score

Original 10-year CHD/CVD risk; derived from US population
Variables: age, sex, TC, HDL, SBP, treatment, smoking, diabetes
May underestimate risk in GCC/Middle Eastern populations
Still used in many GCC facilities as familiar tool

ACC/AHA Pooled Cohort Equations

10-year ASCVD risk; includes race (White/Black/Other)
Variables: age, sex, race, TC, HDL, SBP, BP treatment, DM, smoking
Known to overestimate risk in some populations
Included in ACC/AHA 2019 guidelines — widely referenced in GCC

GCC-Specific Considerations

Qatar: Qatar Metabolic and Cardiovascular Disease Registry; high DM/obesity prevalence
Saudi Arabia: Saudi Heart Association uses SCORE + local risk factor data
UAE: Abu Dhabi CVD Programme; UAE National Screening Programme data
GCC populations may have higher CVD risk than calculators suggest due to DM burden and sedentary lifestyle — apply clinical judgment

Risk calculators are starting points. Nurse role: ensure accurate data entry, identify risk-enhancing factors, and support shared decision-making.

LDL-C Targets by Risk Category (ESC 2021)

Risk Category	Definition	LDL-C Target	Non-HDL Target
Very High Risk	Established ASCVD; DM with organ damage; SCORE2 ≥10%; CKD eGFR <30; FH + another major risk factor	<1.4 mmol/L AND ≥50% reduction from baseline	<2.2 mmol/L
High Risk	Markedly elevated single risk factor (TC >8 or BP >180/110); SCORE2 ≥5% and <10%; most DM (>10 yrs); CKD eGFR 30–59; FH without major risk factors	<1.8 mmol/L AND ≥50% reduction from baseline	<2.6 mmol/L
Moderate Risk	SCORE2 ≥2.5% and <5% (40–49 yrs); young DM (<10 yrs, no risk factors)	<2.6 mmol/L	<3.4 mmol/L
Low Risk	SCORE2 <2.5% (40–49 yrs); no significant risk factors	<3.0 mmol/L	<3.8 mmol/L

The 50% reduction rule applies to very high and high risk regardless of baseline LDL. A patient with LDL of 1.6 who needs 50% reduction still requires a target of 0.8 mmol/L — important when intensifying therapy.

Familial Hypercholesterolaemia (FH)

Dutch Lipid Clinic Network (DLCN) Score

Criterion	Points
1st-degree relative with premature CVD OR known high LDL	1
1st-degree relative with tendon xanthomata OR children <18 with LDL >3.5	2
Premature coronary artery disease (self)	2
Premature cerebrovascular/peripheral arterial disease	1
Tendon xanthomata (self)	6
Arcus cornealis before age 45	4
LDL-C 8.5+ mmol/L	8
LDL-C 6.5–8.4 mmol/L	5
LDL-C 5.0–6.4 mmol/L	3
LDL-C 4.0–4.9 mmol/L	1
DNA mutation in LDLR, ApoB, PCSK9	8

1–2: Unlikely FH 3–5: Possible FH 6–8: Probable FH >8: Definite FH

FH in GCC Context

Autosomal dominant — 1 in 200–500 in general population
Higher prevalence in GCC due to consanguineous marriages (founder effects in Lebanon, Jordan, Gulf, North Africa)
Heterozygous FH: LDL typically 5–10 mmol/L; lifetime CVD risk 50% by age 50 (untreated)
Homozygous FH (rare): LDL >13 mmol/L; CVD in childhood

Cascade Screening (Nurse Role)

Once proband identified: test all 1st-degree relatives
Children of FH parent: screen from age 5–10
GCC barrier: stigma, family privacy concerns around genetic testing
Nurse educates: "This is a treatable inherited condition — family members may benefit from early treatment"

FH patients are automatically Very High Risk if they have CVD, or High Risk if no CVD. Start high-intensity statin immediately upon diagnosis.

Interactive: LDL Target Checker

Calculate LDL Target and Treatment Gap

Patient Risk Category

Current LDL-C (mmol/L)

Baseline LDL-C (mmol/L)

Interactive: Cardiovascular Risk Estimator (Simplified)

Approximate 10-Year CVD Risk (%)

This is a simplified educational estimator only. Use validated clinical tools (SCORE2, PCE) for actual patient care decisions.

Age (years)

Sex

Smoker?

Systolic BP (mmHg)

Total Cholesterol (mmol/L)

HDL-C (mmol/L)

Diabetes?

Mechanism of Action

Statins competitively inhibit HMG-CoA reductase — the rate-limiting enzyme in cholesterol biosynthesis. Reduced hepatic cholesterol → upregulation of LDL receptors → increased LDL clearance from plasma. Pleiotropic effects: anti-inflammatory, plaque stabilisation, endothelial function improvement.

Statin Potency Comparison

Statin	Intensity	Dose	Approx LDL-C Reduction	CYP Metabolism	GCC Availability
Rosuvastatin	High	20–40 mg	45–55%	CYP2C9 (minimal CYP3A4)	Widely Available
Atorvastatin	High	40–80 mg	45–55%	CYP3A4	Widely Available
Simvastatin	Moderate	20–40 mg	35–45%	CYP3A4 (HIGH — interaction risk)	Available
Pravastatin	Moderate	40–80 mg	30–40%	Not CYP (preferred in interactions)	Available
Fluvastatin	Moderate	40–80 mg	25–35%	CYP2C9	Limited
Lovastatin	Moderate / Low	20–40 mg	25–40%	CYP3A4	Limited
Pitavastatin	Moderate	2–4 mg	35–45%	Minor CYP2C9; less DM risk	Some GCC

High-intensity statin = ≥50% LDL-C reduction. Moderate-intensity = 30–49%. Low-intensity = <30%.

Statin Side Effects — Nursing Management

Myopathy Spectrum

Condition	CK Level	Symptoms	Action
Myalgia	Normal (<3×ULN)	Muscle aches, no weakness	Reassure, consider CoQ10 (evidence weak), switch statin
Myositis	3–10×ULN	Muscle pain + weakness	Withhold statin, monitor CK weekly
Rhabdomyolysis	>10×ULN + symptoms	Severe pain, dark urine, weakness	STOP statin immediately, IV fluids, monitor creatinine/K+/urine output

Measure CK only if symptomatic. Routine CK monitoring not recommended. CK can be elevated post-exercise — check in rested state.

Risk Factors for Myopathy

Higher statin dose
Drug interactions (CYP3A4)
Female sex, small body frame
Age >75 years
Hypothyroidism (uncontrolled)
CKD, hepatic impairment
Vigorous exercise
Alcohol excess
Asian ethnicity (lower rosuvastatin dose — 5–10 mg)

Liver Effects

True statin-induced liver injury is rare (<0.001%)
Mild transaminase elevation (1–3×ULN) common, usually transient, not clinically significant
Routine LFT monitoring not recommended (ESC/ACC/AHA guidelines)
Baseline LFTs recommended before initiation
Stop statin if ALT >3×ULN on two measurements

New-Onset Diabetes

High-intensity statins: 10–20% relative risk increase in new-onset DM
Absolute risk small (<1% per year); benefit from CVD reduction far outweighs risk
Does not affect patients already diabetic
Monitor HbA1c/fasting glucose annually in at-risk patients
Pitavastatin may have lower DM risk

Nurse education key point: "The benefit of statins in reducing heart attacks and strokes far outweighs the small risk of diabetes. Statins do not cause muscle disease in most people — only 5–10% experience any muscle discomfort."

Drug Interactions

Statin	Interacting Drug	Mechanism	Risk	Management
Simvastatin / Lovastatin	Clarithromycin, Erythromycin	CYP3A4 inhibition	Rhabdomyolysis	AVOID — suspend statin during course or switch to pravastatin
Simvastatin / Lovastatin	Fluconazole, Itraconazole	CYP3A4 inhibition	Rhabdomyolysis	AVOID — switch to pravastatin/rosuvastatin
Simvastatin / Lovastatin	Amiodarone	CYP3A4 inhibition	Myopathy	Max simvastatin 20 mg with amiodarone
All statins	Ciclosporin	Multiple transporters	High myopathy risk	Use lowest statin dose; pravastatin or fluvastatin preferred
All statins	Gemfibrozil	OATP1B1 inhibition	Myopathy	AVOID combination — use fenofibrate instead
Rosuvastatin	Warfarin	CYP2C9 inhibition	↑ INR	Monitor INR closely after starting
Atorvastatin	Diltiazem, Verapamil	CYP3A4 inhibition (moderate)	Increased levels	Use lower atorvastatin dose; monitor for myalgia

Red flag interaction in GCC: Patients on simvastatin who are prescribed clarithromycin for community-acquired respiratory infection (very common in GCC winters) — nurse must flag this and recommend statin suspension or switch.

Ezetimibe

Mechanism

Inhibits NPC1L1 transporter in intestinal brush border
Reduces intestinal cholesterol absorption by ~50%
Compensatory increase in LDL receptors
LDL-C reduction: 15–20% additional (on top of statin)

Clinical Use

Add-on to statin when LDL-C target not achieved
First-line in statin intolerance
IMPROVE-IT trial: statin + ezetimibe → further 6.4% relative CVD risk reduction
Well tolerated; minimal side effects
Can be combined with all statins

Practical Points

Dose: 10 mg once daily (standard; no dose titration)
Can be taken at any time of day
Available as combination tablets (simvastatin/ezetimibe, atorvastatin/ezetimibe)
No significant drug interactions
Available across GCC — generally affordable

In GCC, where PCSK9 inhibitors may be restricted, ezetimibe is the practical first step when statin alone is insufficient. Nurse can reinforce adherence: "Ezetimibe works differently from your statin — it blocks cholesterol from your food."

PCSK9 Inhibitors

Mechanism and Agents

PCSK9 degrades LDL receptors — inhibiting PCSK9 → more LDL receptors on hepatocytes → more LDL clearance
Evolocumab (Repatha): 140 mg SC every 2 weeks OR 420 mg SC monthly
Alirocumab (Praluent): 75–150 mg SC every 2 weeks
LDL-C reduction: 50–60% on top of maximally tolerated statin
FOURIER (evolocumab) and ODYSSEY (alirocumab) trials: significant MACE reduction

Indications

Very high-risk patients not at LDL target on maximum statin + ezetimibe
Familial hypercholesterolaemia (especially homozygous FH)
Statin intolerance with uncontrolled LDL-C

GCC Access and Nursing Role

Expensive — requires prior approval from insurance/formulary committee in most GCC countries
Saudi Arabia MOH: approved for FH and ASCVD with LDL >2.6 on maximal therapy
UAE/Qatar: available in tertiary centres; biosimilars emerging
Nurse education on SC injection technique, auto-injector use, storage (refrigerated 2–8°C)
Can be left at room temperature for 30 minutes before injection
Rotate injection sites: abdomen, thigh, upper arm

Side effects: mild injection site reactions; generally very well tolerated. No myopathy risk — safe in statin-intolerant patients. Neurocognitive concerns (from early data) not confirmed in large trials.

Inclisiran (RNA-based)

Newer siRNA: 284 mg SC twice yearly after initial doses. Similar LDL-C reduction. Emerging availability in GCC — very convenient dosing improves adherence.

Fibrates

Mechanism and Effects

Activate PPAR-alpha → increased lipoprotein lipase, reduced VLDL synthesis
TG reduction: 30–50%
HDL increase: 10–20%
Modest LDL-C effect (may increase LDL in hypertriglyceridaemia)
Agents: fenofibrate, bezafibrate, gemfibrozil

Clinical Indications

Primary: severe hypertriglyceridaemia (TG >5.6 mmol/L)
TG >11 mmol/L with pancreatitis risk — urgent treatment
Mixed dyslipidaemia (high TG + low HDL) as add-on

Key Points and Safety

Fenofibrate preferred when combining with statins — lower myopathy risk than gemfibrozil
AVOID gemfibrozil + statins — significant OATP1B1 inhibition → increased statin levels → myopathy
Fenofibrate: monitor creatinine (can reversibly increase serum creatinine — not true renal injury)
Dose adjust in CKD (fenofibrate avoided in eGFR <30)
Gallstone risk: increased cholesterol in bile

No proven CVD benefit from fibrates in statin-treated patients (ACCORD trial). Use primarily for TG management and pancreatitis prevention, not for LDL-C lowering.

Omega-3 Fatty Acids & Bile Acid Sequestrants

Omega-3 (Icosapentaenoic Acid)

High-purity EPA (icosapentaenoic acid): REDUCE-IT trial — 4g/day icosapentaenoic acid ethyl ester (Vascepa) → 25% relative MACE reduction in patients on statins with TG 1.5–5.6 mmol/L
TG lowering: 20–30% at high doses
Mechanism: reduces hepatic VLDL synthesis, improves TG clearance
Regular fish oil supplements (DHA+EPA): TG lowering but no proven CV benefit in recent trials
Dose: 2–4 g/day (prescription-grade for TG lowering)
Side effects: fishy aftertaste, GI upset, mild antiplatelet effect

Bile Acid Sequestrants (BAS)

Cholestyramine, Colestipol, Colesevelam
Mechanism: bind bile acids in gut → more cholesterol converted to bile acids → upregulation of LDL receptors
LDL-C reduction: 15–25%
No systemic absorption — safe in pregnancy (only option with statins contraindicated)
Side effects: GI (constipation, bloating, nausea) — limits adherence

Drug interactions: BAS bind many drugs in the gut — take other medications 1 hour before or 4–6 hours after BAS (warfarin, digoxin, thyroid hormones, statins if combined).

Colesevelam also lowers HbA1c — can be useful in DM + dyslipidaemia. Available in some GCC tertiary centres.

Hypertriglyceridaemia Management

GCC-Specific Causes

Obesity — BMI >30 in 30–40% of GCC adults
Type 2 Diabetes / Insulin Resistance — very high prevalence in GCC
High refined carbohydrate diet — white rice, bread, sugary beverages, dates in excess
Alcohol — underreported in GCC; note: some non-alcoholic beverages may contain small amounts
Hypothyroidism — common, especially in women
Nephrotic Syndrome
Genetic causes: familial hypertriglyceridaemia, Type III hyperlipidaemia (apoE2/E2)

Classification

Normal: <1.7 mmol/L Borderline: 1.7–5.6 High: 5.6–11.0 Very High: >11 mmol/L

Pancreatitis Risk Management

TG >11 mmol/L = acute pancreatitis risk. Urgent intervention required.

Step 1: Lifestyle — low-fat diet (<20% kcal from fat), eliminate alcohol, treat DM, lose weight. Can reduce TG by 20–50%.
Step 2: Fibrate (fenofibrate 145–200 mg/day) — most effective pharmacological TG reduction
Step 3: Add omega-3 (prescription grade) if TG remains elevated
Step 4: Combination fenofibrate + omega-3
Hospital: If admitted with hypertriglyceridaemia pancreatitis — NPO, IV fluids, consider insulin infusion to rapidly lower TG; plasmapheresis in extreme cases (>40 mmol/L)

Statin Intolerance

True Myopathy vs Perceived Intolerance

True statin myopathy with elevated CK: <1% of patients
Statin-associated muscle symptoms (SAMS) reported in 5–10% — mostly not true myopathy
Nocebo effect: patients expecting side effects experience them more
SAMSON trial: 90% of symptoms on statin were also reported on placebo (nocebo effect)

Rechallenge Protocol

Stop index statin — allow washout (4–6 weeks)
Confirm CK normalises
Rechallenge with rosuvastatin 5 mg alternate days (longest half-life, minimal CYP3A4)
Slowly titrate up
If truly intolerant to all statins: ezetimibe + PCSK9 inhibitor

GCC Nursing Considerations

Very common patient concern: "statins damage muscles / liver / kidneys" — widespread misconception in GCC
Social media in Arabic promoting statin fear — nurse must address directly
CoQ10 supplementation: evidence is weak — not routinely recommended, but can be offered for patient satisfaction
Check vitamin D levels (deficiency common in GCC, despite sun exposure due to indoor lifestyle) — vitamin D deficiency can cause musculoskeletal symptoms attributed to statins
Check TSH — hypothyroidism causes myalgia and can be confused with statin side effects

Key nurse message: "If you stop your statin without telling your doctor, your risk of a heart attack increases significantly. Please discuss any side effects with us — we have solutions."

Special Populations

Chronic Kidney Disease (CKD)

CKD independently increases CVD risk — most CKD patients are high or very high CVD risk
Rosuvastatin preferred — least renal excretion; not dose-adjusted until eGFR <30
Atorvastatin: safe across all stages of CKD
Simvastatin 40 mg + Ezetimibe: used in SHARP trial (CKD) — significant MACE reduction
Avoid high-dose simvastatin (>20 mg) in advanced CKD — myopathy risk
Fibrates: dose-adjust or avoid in eGFR <30
Statins do not slow CKD progression (no renoprotective effect)

Elderly (>75 years)

Benefit established in those with existing CVD (secondary prevention)
Primary prevention in elderly: risk/benefit discussion; frailty assessment important
Use lower doses; more susceptible to drug interactions and myopathy
SCORE2-OP for patients ≥70 years (different thresholds)

Pregnancy

Statins are CONTRAINDICATED in pregnancy (Category X) — teratogenic in animal studies; insufficient human safety data.

Discontinue statins when planning pregnancy, at positive pregnancy test, and during breastfeeding
Cholesterol is essential for fetal development
FH in pregnancy: if LDL very high (>5 mmol/L) — bile acid sequestrants (cholestyramine) can be used (not absorbed)
LDL apheresis considered for homozygous FH in pregnancy
Statins can be restarted after delivery and cessation of breastfeeding

Type 1 and Type 2 Diabetes

All T2DM patients >40 years: statin (regardless of LDL) — guidelines-based
T1DM: statin if >10 years duration or ≥40 years or with nephropathy
DM = independent CVD risk enhancer — may upgrade risk category
Statins slightly worsen glycaemia — monitor HbA1c but do not stop statin for this reason

Mixed Dyslipidaemia

Mixed dyslipidaemia = elevated LDL + elevated TG + low HDL. Common in GCC — strongly associated with MetS, T2DM, obesity.

Management Priority

Address secondary causes first (DM control, weight loss, thyroid)
Treat LDL-C to target — statin is primary therapy
If TG >5.6 mmol/L after statin: add fenofibrate
Non-HDL-C = secondary target (LDL target + 0.8 mmol/L)
Low HDL: lifestyle (exercise, smoking cessation, weight loss) — no proven drug therapy to raise HDL beneficially

Atherogenic Dyslipidaemia Pattern

Elevated TG, low HDL, small dense LDL
Classic in T2DM and metabolic syndrome
LDL-C may appear "normal" — but small dense LDL is more atherogenic per particle
ApoB and non-HDL-C more informative than LDL-C in this pattern
Statin + fenofibrate combination addresses all components

Dyslipidaemia Burden in GCC

50–60%

Prevalence of dyslipidaemia in some GCC surveys (UAE, KSA, Kuwait)

1 in 100

Estimated FH prevalence in some GCC populations (vs 1:500 globally) — consanguinity effect

<50%

Statin adherence at 12 months in GCC studies — far below target

Dietary Contributors

Ghee (samn): High saturated fat — widely used in traditional GCC cooking
Red meat: High consumption in GCC (kabsa, mandi, harees)
Fried foods: Samboosa, luqaimat — trans fats and saturated fat
Refined carbohydrates: White rice, bread, sugary beverages — drive hypertriglyceridaemia
Dates: High in natural sugars — moderate intake fine, excess elevates TG
Low physical activity: Indoor lifestyle due to heat; limited walking culture

Statin Adherence Barriers

Fear of side effects (muscle damage, liver damage — often from social media)
Belief that statins are "lifelong chemicals" — patient prefers "natural" remedies
Language barriers — Arabic patient education materials often scarce
Polypharmacy burden (many patients on 5–10 medications)
Cost (statins generally affordable, but PCSK9 inhibitors expensive)
Asymptomatic condition — patient does not "feel" dyslipidaemia improving

Nurse role: structured medication counselling in Arabic, myth-busting, simplified regimens (once daily dosing preferred), follow-up lipid results shared with patients as positive reinforcement.

Ramadan and Lipid Management

Potential Benefits

Caloric restriction → weight loss → improved TG and HDL
Improved insulin sensitivity in some patients
Reduction in snacking and processed food during daylight hours
Spiritually motivated lifestyle change — teachable moment

Potential Harms

Late-night high-calorie feast (Iftar, Suhoor): high fat, high sugar intake
Reversal of positive effects if diet quality poor
Reduced physical activity (fatigue during fasting hours)
Irregular medication timing — statin may be missed
Dehydration can affect lipid measurements

Medication Advice During Ramadan

Statins: Most can be taken at Suhoor or Iftar — no fasting restriction. Simvastatin: take at Iftar (evening preferred for short half-life). Rosuvastatin/Atorvastatin: time-independent.
Fenofibrate: Take with main meal (Iftar)
Ezetimibe: Any time with Iftar or Suhoor meal
Avoid scheduling lipid panels during Ramadan — results may not reflect true baseline

Nurse Ramadan education: "This is an excellent time to improve your diet and activity. However, be careful about what you eat at Iftar — avoid deep-fried starters and excessive sweets."

GCC National CVD Prevention Programmes

Country / Programme	Key Initiatives	Lipid Relevance
UAE — Abu Dhabi CVD Prevention Programme (ADCVP)	Population screening; SEHA health network integration; national NCD strategy	Statin prescribing targets; lipid screening protocol
Saudi Arabia — Saudi Heart Association (SHA)	SHA 2020 lipid guidelines; PCSK9 criteria; FH registry	Aligned with ESC 2019/2021; statin intensity recommendations
Qatar — Qatar National Diabetes & CVD Programme	Integrated DM-CVD risk management; Sidra/HMC pathways	Lipid targets embedded in DM pathways
Kuwait — Kuwait Heart Foundation	Community awareness; cardiac rehabilitation	Statin use guidelines
Bahrain / Oman	MOH chronic disease programmes; primary health care lipid screening	Basic lipid panel in annual check-ups

GCC nurses should familiarise themselves with local MOH formularies — statin choices and PCSK9 availability vary by hospital and insurance tier. PCSK9 inhibitors typically require specialist (cardiologist/endocrinologist) initiation and prior authorisation.

Familial Hypercholesterolaemia in GCC — Under-Diagnosis Crisis

Estimated 1 in 200–500 globally; estimated up to 1 in 100 in some GCC populations due to founder effects and consanguinity
Most remain undiagnosed — presenting only after first MI
Nurse role in detection: note LDL >4.9 mmol/L → ask about family history of early CVD or high cholesterol
Examine for tendon xanthomata (Achilles, knuckles), arcus cornealis before age 45, xanthelasma
Refer to lipid clinic / genetic services when suspected
Family cascade: offer testing to first-degree relatives — frame positively as "early detection saves lives"
Child of FH parent: 50% chance of inheriting FH — screen from age 5–10 years
Homozygous FH (both alleles affected): CVD in teens/20s — requires apheresis ± lomitapide ± PCSK9 inhibitors (limited access in GCC)